Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

A Multi-modal Cohort Study of Brown Adipose Tissue Based on Paired Comparisons at Room Temperature and After Cold Exposure

NCT07908719 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2026-10-01
Last updated
2026-11-02

Condition(s) studied

Brown Adipose Tissue, Human

Investigational drug(s) / intervention(s)

cold exposure

cold exposure: Participants will undergo saliva and blood collection and complete PET-CT scans both at room temperature and after cold exposure. The room-temperature PET-CT scan will be performed according to routine clinical protocols without the need for additional oral or injectable medications. For the post-cold-exposure scan, participants will only need to receive 2 hours of moderate cold exposure prior to the scan to adequately activate brown adipose tissue (they will be arranged to rest in a room maintained at 16-19 °C).

Study summary

This study is a single-center, prospective clinical study that plans to prospectively recruit volunteers aged 18-40 years, including metabolically healthy individuals and those with diabetes mellitus and hyperlipidemia. Participants will undergo \[¹⁸F\]fluorodeoxyglucose positron emission tomography/computed tomography (\[¹⁸F\]FDG PET/CT) scans both at room temperature and after cold exposure. The planned sample size is 500 participants. The study will systematically collect baseline data, questionnaire responses, \[¹⁸F\]FDG PET/CT images acquired under both conditions, as well as saliva and blood samples.

The study aims to establish a clinical-imaging-biological multimodal brown adipose tissue (BAT) cohort with paired pre- and post-cold exposure comparisons. Based on this cohort, we expect to achieve new breakthroughs in BAT detection methods, assessment criteria, and the understanding of its genetic mechanisms.

Eligibility

Sex
ALL
Min age
18 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Aged 18 to 40 years, regardless of sex; * Stable body weight within the past 3 months, with a weight change of \< 3 kg; * Able to tolerate the cold exposure test (without severe cold allergy, Raynaud's phenomenon, cold urticaria, or other related conditions). Exclusion Criteria: * Any diagnosed chronic metabolic disease (excluding diabetes mellitus and hyperlipidemia); no major organic diseases (including but not limited to cardiovascular, respiratory, endocrine, neuropsychiatric disorders) and no history of malignancy * Pregnant women, breastfeeding women, or those planning to become pregnant during the study period; * Use of β-blockers (e.g., propranolol), benzodiazepines (e.g., diazepam), or other medications that may affect brown adipose tissue metabolism (such as glucocorticoids, sympathomimetic agents, some antidepressants, etc.) within the past 4 weeks, as determined by the investigator; * Presence of contraindications to PET-CT examination (e.g., claustrophobia, inability to remain supine for 30 minutes, allergy to FDG, etc.);

Primary outcome measure(s)

  • brown adipose tissue at baseline — Baseline at room-temperature
    The volume of brown adipose tissue at room-temperature. BAT was diagnosed on ¹⁸F-FDG PET-CT according to BARCIST 1.0, defined as areas with SUVbm ≥ 1.5 on PET and CT Hounsfield units between -190 and -10, after excluding obvious non-fat tissues within this range such as lung.
  • brown adipose tissue at baseline — Baseline at room-temperature
    The SUVmax of brown adipose tissue at room-temperature. BAT was diagnosed on ¹⁸F-FDG PET-CT according to BARCIST 1.0, defined as areas with SUVbm ≥ 1.5 on PET and CT Hounsfield units between -190 and -10, after excluding obvious non-fat tissues within this range such as lung.
  • brown adipose tissue at baseline — Baseline at room-temperature
    The SUVmean of brown adipose tissue at room-temperature. BAT was diagnosed on ¹⁸F-FDG PET-CT according to BARCIST 1.0, defined as areas with SUVbm ≥ 1.5 on PET and CT Hounsfield units between -190 and -10, after excluding obvious non-fat tissues within this range such as lung.
  • brown adipose tissue after cold exposure — After 2-hour cold exposure within 2 weeks
    The volume of brown adipose tissue after 2-hour cold exposure. BAT was diagnosed on ¹⁸F-FDG PET-CT according to BARCIST 1.0, defined as areas with SUVbm ≥ 1.5 on PET and CT Hounsfield units between -190 and -10, after excluding obvious non-fat tissues within this range such as lung.
  • brown adipose tissue after cold exposure — After 2-hour cold exposure within 2 weeks
    The SUVmax of brown adipose tissue after 2-hour cold exposure. BAT was diagnosed on ¹⁸F-FDG PET-CT according to BARCIST 1.0, defined as areas with SUVbm ≥ 1.5 on PET and CT Hounsfield units between -190 and -10, after excluding obvious non-fat tissues within this range such as lung.
  • brown adipose tissue after cold exposure — After 2-hour cold exposure within 2 weeks
    The SUVmean of brown adipose tissue after 2-hour cold exposure. BAT was diagnosed on ¹⁸F-FDG PET-CT according to BARCIST 1.0, defined as areas with SUVbm ≥ 1.5 on PET and CT Hounsfield units between -190 and -10, after excluding obvious non-fat tissues within this range such as lung.

Trial sites (1)

FacilityCityRegionStatus
Jinling Hospital Nanjing Jiangsu Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07908719 on ClinicalTrials.gov ↗ ← All trials in China